The 5,000 Shares of DexCom Inc. (DXCM) Stock are sold by Andrew K. Balo

The 5,000 Shares of DexCom Inc. (DXCM) Stock are sold by Andrew K. Balo

DexCom Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 5,000 shares of the stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $82.55, for a total transaction of $412,750.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Andrew K. Balo also recently made the following trade(s): On Wednesday, September 21st, Andrew K. Balo sold 5,000 shares of DexCom stock. The shares were sold at an average price of $92.87, for a total transaction of $464,350.00.

DexCom Inc. (NASDAQ:DXCM) opened at 82.93 on Friday. The stock’s 50 day moving average is $90.88 and its 200-day moving average is $77.91. The firm’s market capitalization is $6.96 billion. DexCom Inc. has a one year low of $47.92 and a one year high of $96.38.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.12. The business earned $137.30 million during the quarter, compared to the consensus estimate of $132.48 million. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. The company’s revenue was up 47.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.05) earnings per share. On average, analysts anticipate that DexCom Inc. will post ($0.57) EPS for the current fiscal year.

Large investors have recently made changes to their positions in the company. Loomis Sayles & Co. L P raised its stake in shares of DexCom by 0.4% in the first quarter. Loomis Sayles & Co. L P now owns 25,898 shares of the medical device company’s stock worth $1,759,000 after buying an additional 94 shares during the last quarter. Public Employees Retirement Association of Colorado raised its stake in shares of DexCom by 0.5% in the second quarter. Public Employees Retirement Association of Colorado now owns 19,466 shares of the medical device company’s stock worth $1,544,000 after buying an additional 94 shares during the last quarter. Hsbc Holdings PLC raised its stake in shares of DexCom by 2.6% in the second quarter. Hsbc Holdings PLC now owns 3,944 shares of the medical device company’s stock worth $313,000 after buying an additional 100 shares during the last quarter. Eqis Capital Management Inc. raised its stake in shares of DexCom by 1.7% in the second quarter. Eqis Capital Management Inc. now owns 7,246 shares of the medical device company’s stock worth $575,000 after buying an additional 119 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its stake in shares of DexCom by 4.0% in the second quarter. Metropolitan Life Insurance Co. NY now owns 6,183 shares of the medical device company’s stock worth $490,000 after buying an additional 239 shares during the last quarter. Hedge funds and other institutional investors own 99.37% of the company’s stock.

Several research firms have recently issued reports on DXCM. B. Riley began coverage on shares of DexCom in a research note on Monday, September 26th. They set a “neutral” rating and a $97.00 price target for the company. BTIG Research reaffirmed a “buy” rating and set a $92.00 price target on shares of DexCom in a research note on Thursday, August 4th. Canaccord Genuity reaffirmed a “buy” rating and set a $95.00 price target on shares of DexCom in a research note on Wednesday, July 13th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $93.00 price target on shares of DexCom in a research note on Friday, July 15th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of DexCom in a research note on Monday, June 20th. One analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $95.08.

About DexCom

Related posts

Leave a Comment